(291) Biological evaluation of lycopene-loaded silica-based nanoparticle for vulvovaginal candidiasis

Introduction: Candida albicans resistant strains make vulvovaginal candidiasis (VVC) a health problem, requiring new treatment options, as lycopene (LYC). Despite LYC features that limit its therapeutic application its association with nanoparticles[1], like mesoporous silica nanoparticles (MSN), seems to surpass it. Though, during LYC@MSN development, organic residues in the MSN was noted, probably from cetyltrimethylammonium bromide (CTAB), toxic to cells[2,3]. This study aimed to assess LYC@MSN, LYC, MSN and CTAB activity against C. albicans strains and their toxicity by an alternative in vivo model.